Ctxr offering
WebCTXR Analyst Research CTXR Analyst Ratings Consensus Strong Buy Based on 3 analysts offering recommendations for 'CTXR' in the last 3 months. Analyst Firms Making Recommendations DAWSON... WebApr 13, 2024 · April 13, 2024 Citius Pharmaceuticals Inc. (CTXR) stock is currently valued at $1.57. During the last session, the stock experienced a remarkable rise, reaching $1.59 after opening at $1.54. The stock briefly dropped to $1.48 before ultimately closing at $1.53.
Ctxr offering
Did you know?
WebCTXR 2M Long Term test Citius Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives … WebMar 24, 2024 · CTXR Earnings Date and Information. Citius Pharmaceuticals last posted its earnings results on February 10th, 2024. The reported ($0.04) earnings per share for the …
WebCitius Pharmaceuticals Inc (CTXR) Try Excel Alerts Watch Help Go To: Full Chart Realtime quote and/or trades are not sourced from all markets. Fundamentals Market Capitalization, $K 200,373 Shares Outstanding, K 146,258 Annual Sales, $ 0 K Annual Income, $ -33,640 K 60-Month Beta 1.38 Price/Sales N/A Price/Cash Flow N/A … Web20 hours ago · Research for CTXR Price to Free Cash Flow Second Metric About Price to Free Cash Flow The Price to Free Cash Flow ratio or P/FCF is price divided by its cash flow per share. It's another great...
WebFeb 19, 2024 · It was founded in 2010 and joined the public market via an initial public offering (IPO) in September 2014. ... N.J. CTXR stock was up 23.8% as of Friday … Web18 hours ago · View Citius Pharmaceuticals, Inc CTXR investment & stock information. Get the latest Citius Pharmaceuticals, Inc CTXR detailed stock quotes, stock data, Real-Time …
Web2 days ago · Company Profile CTXR. Business Description. Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, unique …
WebAug 10, 2024 · Citius Pharmaceuticals Announces Closing of $9.6 Million Bought Deal Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares /PRNewswire/ -- Citius Pharmaceuticals,... cymbalta medication mechanismWebFeb 19, 2024 · It’s worth noting that the company announced a direct offering on Wednesday for 50,830,566 shares and warrants for another 25,415,283 shares. That … billy itule arizonaWebCTXR Stock 12 Months Forecast. $5.00. (327.35% Upside) Based on 2 Wall Street analysts offering 12 month price targets for Citius Pharmaceuticals in the last 3 months. The … billy iusoWebJan 25, 2024 · Corporate News, Equity Offerings Citius Pharmaceuticals (CTXR) Announces $20.0 Million Private Placement of Common Stock, Warrants Article Related … cymbalta memory loss side effectsWebApr 9, 2024 · The S&P 500 ticked slightly higher Monday as investors looked ahead to key inflation data this week. The broader index rose 0.1% to 4,109.11. The Dow Jones Industrial Average added 101.23 points ... billy i\u0027ve got to go to town lyricsWeb2 days ago · NASDAQ: CTXR Last close prices updated as of Apr 04, 2024, 4:00 PM EST USD BATS BZX Real-Time Price Overview Key Ratios Trading Information Last Close 1.32 Sector Healthcare Industry... billy italian vicksburg menuWebFeb 19, 2024 · CRANFORD, N.J., Feb. 19, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that it has closed its previously announced sale of an aggregate of 50,830,566 shares of … billy iuso listen